Bir Sigara Bırakma Polikliniğine Başvuran Hastaların Özellikleri

Year 2021, , 436 - 440, 29.12.2021

Mehmet Kabak , İclal Hocanlı , Barış Çil

https://doi.org/10.35440/hutfd.982507

Abstract

AMAÇ:Sigara, önlenebilir ölüm ve hastalıkların en sık nedenidir. Ülkemiz, Avrupa bölgesinde sigara içme oranı yüksek ülkelerden biridir. Toplumsalbilinçlenme, eğitim ve sosyal durumlar nedeniyle sigara kullananların,sigara bırakma polikliniklerine başvuruları arttırmaktadır. Bu çalışmada, hem sigara polikliniğimizdeki sigara bırakma durumunu hem de sigara bırakma için 12 haftalık standart bir vareniklin rejimini ve 10 haftalık standart bir transdermal nikotin replasman tedavisi (NRT) rejiminin bırakma üzerindeki etkisini tartışmayı amaçladık.
MATERYAL METOD: Bu çalışmaya Ocak 2015 ve Ocak 2018 yılları arasında sigara bırakma polikliniğine başvuran, sigara bırakma tedavisi başlanmış 845 hasta retrospektifolarak incelendi.
BULGULAR: Çalışmaya dahil edilen hastalarda yaş ve cinsiyet açısından istatiksel olarak anlamlı sonuç elde edilmedi (p=0.622, p=0.241). Sigara bırakan gruptaFNBS 6.12±0.9 iken, sigara bırakmayan grupta 8.45±1.1 idi ve gruplar arasında istatiksel olarak anlamlı farklılık saptandı (p=0,04). Hastaların %80.5’ivareniklin, %19.5’i nikotin bandı kullanmıştı. Sigara bırakmada Vareniklin ve nikotin bandı arasında istatistiksel anlamlı fark saptanmadı (p=0.709, p=0.710).
SONUÇ: Yaş ve cinsiyet gibi verilerin sigara bırakmayı etkilemediği, ancak FNBS düşük olmasının sigarayı bırakmada etkili olduğu görüldü. Tümsigara içenlere davranışsaleğitimin yanında uygun farmakolojik destek tedavisi de verilmelidir.

Keywords

Sigara Bırakma, Vareniklin, Nikotin Replasman Tedavisi

Characteristics of Patients Admitted to a Smoking Cessation Policlinic

Abstract

BACKGROUND: Smoking is the most common cause of preventable death and illness.
Our country is one of the countries with a high rate of smoking in the European region. Due to social awareness, education and social conditions, the applications of smokers to smoking cessation outpatient clinics are increasing. In this study, we aimed to discuss both the smoking cessation status in our smoking outpatient clinic and the effect of a standard 12-week vareniclin eregimen for smoking cessation and a standard 10-week transdermal nicotine replacement therapy (NRT) regimen on cessation.
METHODS: 845 patients who applied to smoking cessation clinic between January 2015 andJanuary 2018 were started retrospectively.
RESULTS: No statistically significant results were obtained in terms of age and gender in the patients included in the study (p=0.622, p=0.241). FNBS was 6.12 ± 0.9 in the smoking group, and 8.45 ± 1.1 in thenon-smoking group, and a statistically significant difference was found between the groups (p = 0.04). 80.5% of the patients used varenicline, 19.5% used nicotine patch. There was no statistically significant difference between varenicline and nicotine band (p = 0.707).
CONCLUSİONS: It was observed that data such as age and gender did not affect smoking cessation, but low FNBS was effective in quitting smoking. All smokers should be given appropriate pharmacological support therapy, in addition to behavioral training.

Keywords

Smoking Cessation, Varenicline, Nicotine Replacement Therapy

References

• 1.Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoSMed. 2006;3(11):e442. doi: 10.1371/journal.pmed.0030442.
• 2. Yaşar Z, Kurt ÖK, Talay F, Kargı A. One-Year Follow up Results of Smoking Cessation Outpatient Clinic: Factors Affecting The Cessation of Smoking. Eurasian J Pulmonol 2014; 16(2): 99-104
• 3.Fiore MC. Treating to baccouse and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. RespirCare. 2000;45(10):1196-9.
• 4. Tønnesen P, Carrozzi L, Fagerström KO, Gratziou C, Jimenez-Ruiz C, Nardini S, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. EurRespir J. 2007;29(2):390-417.
• 5.Berkeşoğlu Ç, Özgür ES, Demir AU. Sigara bırakma başarısını etkileyen faktörler. Mersin Univ Saglık Bilim Derg 2018;11(3):355-65.
• 6.Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-27.
• 7. Abakay Ö, Abakay A, Tanrıkulu AÇ, Şen HS, Sezgi C, Dallı A, et al.. The Outcome of Patients that Admitted to Outpatients of Smoking Cessation. J ChestDisCritCareMed 2014;1(1):7-10
• 8.A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283(24):3244-54.
• 9.Demir T, Tutluoğlu B, Koç N, Bilgin L. Sigara bırakma polikliniğimizin bir yıllık izlem sonuçları. Tüberküloz ve Toraks Dergisi 2004;52:63-8.
• 10.Solak ZA, Telli CG, Erdinç E. Sigara bırakma tedavisinin sonuçları. Tur ToraksDerg 2003; 4(1):73-7.
• 11.Salepçi B, Fidan A, Oruç Ö, Torun E, Çağlayan B. Sigara bırakma polikliniğimizde başarı oranları ve başarıda etkili faktörler. Tur ToraksDerg2005;6:151-8.
• 12.Renaud JM, Halpern MT. Clinical management of smoking cessation: patient factors affecting a reward­based approach. Patient Prefer Adherence 2010;4:441-50.
• 13.Sağlam L. Investigation of theresults of a smoking cessation clinic and the factors associated with succes. Turk J MedSci2012; 42:515-22. 

• 14. Wu PC, Hsueh KC, Mar GY, Hsueh SC, Tu MS, McRobbie H, et al. Gender Differences in Outcome of an Attempt to Stop Smoking Among Smokers Attending a Smoking Cessation Clinic in Taiwan: 3-Year Follow-Up Study. Evaluation &the health professions. 2016; 39(3):317–25
• 15. Smith PH, Kasza KA, Hyland A, Fong GT, Borland R, Brady K, et al. Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey. Nicotine&Tobacco Research. 2015; 17(4):463–72.
• 16. Argüder E, Karezli A, Hezer H, Kılıç H, Er M, Hasanoğlu HC ve ark. Sigara bırakma başarısını etkileyen faktörler. Tur ToraksDerg 2013;14(3): 81-7.
• 17. Janson C, Kunzli N, deMarco R, Chinn S, Jarvis D, Svanes C, et al. Chang- es in active and passive smoking in European Community Respiratory Health Survey. EurRespir J 2006;27(3): 517-24.
• 18.Şahbaz S, Kılınç O, Günay T, Ceylan E. Sigara içme ve demografik özelliklerin sigara bırakma tedavilerinin sonuçlarına etkileri. Tur ToraksDerg 2007;8(2):110-4.
• 19.Patnode CD, Henderson JT, Thompson JH, Senger CA, Fortmann SP, Whitlock EP. Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviewsforthe U.S. Preventive Services Task Force. Annals of internalmedicine. 2015;163(8):608–21.
• 20.Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. Jama. 2014;311 (2):193–4.
• 21.Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacementtherapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Annals of medicine. 2012; 44(6):588–97.
• 21. Anthenelli RM, Benowitz NL, West R, StAubin L, McRae T, Lawrence D et al. Neuropsychiatric safety an defficacy of varenicline, bupropion, and nicotine patch in smokers with and with outpsychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-20.
• 22.Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA. 1994;271(8):589-94.
• 23.Fernandez E, Garcia M, Schiaffino A, Borras JM, Nebot M, Segura A. Smoking initiation and cessation by gender and education al level in Catalonia, Spain. PrevMed. 2001;32(3):218-23.
• 24.Górecka D, Bednarek M, Nowiński A, Puścińska E, Goljan-Geremek A, Zieliński J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003;123(6):1916-23.